Lv5
1230 积分 2023-10-16 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
Group sequential design using restricted mean survival time as the primary endpoint in clinical trials
1个月前
已完结
Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for seamless phase I-II trials in oncology
1个月前
已完结
Leveraging pharmacokinetic parameters as covariate in Bayesian logistic regression model to optimize dose selection in early phase oncology trial
1个月前
已完结
Optimal dose selection in phase I/II dose finding trial with contextual bandits: a case study and practical recommendations
1个月前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
1个月前
已完结
DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior
1个月前
已完结
Demystifying stabilization in inverse probability of treatment weighting
1个月前
已完结
Covariate adjusted dose–response curves with applications to vaccine clinical trials
1个月前
已完结
Common risk difference and corresponding confidence interval adjusted for multiple factors – comparison of seven different methods
2个月前
已完结
皖公网安备34019202002308
